Karyopharm myeloma drug yields mixed data in myelofibrosis trial
BioPharma Dive
Xpovio combined with Incyte s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst s estimates, could triple the company s revenue.
pharminent
March 24, 2026 (Last updated: March 24, 2026)
BioPharma Dive
Xpovio combined with Incyte s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst s estimates, could triple the company s revenue.
